High‐throughput, multiplexed quantification of CaV‐mediated cell responses using synthetic gene circuits combined with in silico virtual screening and deep‐learning‐based prediction identified sclareol as a novel Cav1.3‐antagonist that could evolve as neuroprotective pharmacotherapy of Parkinson's disease in the future. Here, CACNA1D is linked to Parkinson disease.